2181 — Mabpharm Income Statement
0.000.00%
Last trade - 00:00
- HK$1.48bn
- HK$1.58bn
- CNY87.16m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 82.9 | 55.9 | 87.2 |
Cost of Revenue | |||||
Gross Profit | — | — | 66.1 | 40.5 | 75.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 195 | 181 | 372 | 260 | 287 |
Operating Profit | -195 | -181 | -289 | -204 | -200 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -203 | -185 | -292 | -211 | -209 |
Provision for Income Taxes | |||||
Net Income After Taxes | -203 | -185 | -292 | -211 | -209 |
Net Income Before Extraordinary Items | |||||
Net Income | -203 | -185 | -292 | -211 | -209 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -203 | -185 | -292 | -211 | -209 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.046 | -0.045 | -0.071 | -0.051 | -0.051 |